Therapeutic Paradigm Changes in Myasthenia Gravis and Amyotrophic Lateral Sclerosis
- Author:
Seong-il OH
1
Author Information
- Publication Type:Review Article
- From:Journal of the Korean Neurological Association 2026;44(2):124-133
- CountryRepublic of Korea
- Language:Korean
- Abstract: The treatment paradigm for neuromuscular diseases, especially myasthenia gravis and amyotrophic lateral sclerosis, has recently shifted with the emergence of mechanism-based and precision therapies. In myasthenia gravis, improved understanding of antibody-mediated pathology has enabled the clinical adoption of targeted immunotherapies, including complement inhibitors and neonatal Fc receptor antagonists, resulting in meaningful benefits for refractory disease and a shift beyond conventional immunosuppression. In amyotrophic lateral sclerosis, while multidisciplinary care remains fundamental, recent advances highlight a gradual move toward precision medicine through platform trial designs, biomarker-informed evaluation, and gene-specific molecular therapies for selected patient subgroups. Together, these developments reflect a paradigm shift from uniform treatment strategies to individualized, pathophysiology-driven clinical decision-making. This review summarizes recent guideline updates and key clinical trial evidence, illustrating how advances in immunopathology, genetics, and trial methodology are redefining contemporary neuromuscular care.
